Nektar Therapeutics (NKTR) stock is down -1.14% over the last 12 months, and the average rating from Wall Street analysts is a Buy. InvestorsObserver’s proprietary ranking system, gives NKTR stock a score of 35 out of a possible 100.
That rank is mainly influenced by a short-term technical score of 29. NKTR's rank also includes a long-term technical score of 31. The fundamental score for NKTR is 44. In addition to the average rating from Wall Street analysts, NKTR stock has a mean target price of $22.50. This means analysts expect the stock to add 29.76% over the next 12 months.
NKTR has an Overall Score of 35. Find out what this means to you and get the rest of the rankings on NKTR!
Nektar Therapeutics (NKTR) stock has gained 1.58% while the S&P 500 has risen 1.58% as of 12:52 PM on Thursday, Oct 14. NKTR has risen $0.27 from the previous closing price of $17.07 on volume of 367,516 shares. Over the past year the S&P 500 has risen 27.06% while NKTR is down -1.14%. NKTR lost -$2.62 per share in the over the last 12 months.
Click Here to get the full Stock Report for Nektar Therapeutics stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
